Rhythm Pharmaceuticals

Explore the latest insights on Rhythm Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Rhythm Pharmaceuticals’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes
Company

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) announced its financial results for the third quarter of 2026, recording total revenues of USD 108.2 million versus USD 116.1 million a year…

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion

AstraZeneca Proposes ~US$10 Billion Acquisition of Obesity Drugmaker Rhythm Pharmaceuticals – Deal to Be Pursued Through Rare Disease Unit Alexion

AstraZeneca Proposes ~US$10 Billion Acquisition of Obesity Drugmaker Rhythm Pharmaceuticals – Deal to Be Pursued Through Rare Disease Unit Alexion

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now